Vedanta Biosciences Granted First European Patent Broadly Covering Pharmaceutical Compositions for Microbiome Therapeutics Ba...
19 October 2016 - 5:00PM
Business Wire
Vedanta Biosciences, pioneering the development of a novel class
of therapies for immune and infectious diseases based on rationally
designed consortia of bacteria derived from the human microbiome,
today announced that the European Patent Office (EPO) has issued
European Patent EP2575835. The patent broadly covers pharmaceutical
compositions of Clostridium live bacterial strains and further
expands Vedanta Biosciences’ patent portfolio after the issuances
of three U.S. patents in the previous months and earlier issuances
in Japan. The patents are exclusively licensed to Vedanta
Biosciences under an agreement with the University of Tokyo and
provide coverage through at least 2031.
The patented technology is based on ground-breaking work by Dr.
Kenya Honda, a scientific co-founder of Vedanta Biosciences. Dr.
Honda’s work provides an avenue for the treatment of a variety of
diseases including immune and infectious diseases employing
bacterial strains belonging to Clostridium clusters IV and/or XIVa.
Clostridium bacteria include a variety of spore-forming species
that can abundantly colonize the gut.
“This European patent is an important addition to our global
intellectual property portfolio,” said Bernat Olle, Ph.D., Chief
Executive Officer of Vedanta Biosciences. “The claims issued put
Vedanta in a very favorable position to commercialize drugs based
on bacterial consortia in the second largest market in the world.”
said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta
Biosciences.
About Vedanta BiosciencesVedanta Biosciences is
pioneering development of a novel class of therapies for immune and
infectious diseases based on rationally designed consortia of
bacteria derived from the human microbiome, with clinical trials
expected to begin in the first half of 2017. Founded by PureTech
Health (PureTech Health plc, PRTC.L) and a group of world-renowned
experts in immunology and microbiology, Vedanta Biosciences is a
leader in the microbiome field with capabilities to discover,
develop and manufacture drugs based on live bacterial consortia.
Leveraging its proprietary technology platform and the expertise of
its team of scientific cofounders, Vedanta Biosciences has isolated
a vast collection of human-associated bacterial strains and
characterized how the immune system recognizes and responds to
these microbes. This work has led to the identification of human
commensal bacteria that induce a range of immune responses –
including induction of regulatory T cells and Th17 cells, among
others – as well as the characterization of novel molecular
mechanisms of microbial-host communication. These advances have
been published in leading peer-reviewed journals including Science,
Nature (multiple), Cell and Nature Immunology. Vedanta Biosciences
has harnessed these biological insights as well as data from
clinical translational collaborations to generate a pipeline of
programs in development for infectious disease, autoimmune disease,
inflammation and immune-oncology. The clinical potential of
therapeutic manipulation of the microbiome has been validated by
multiple randomized, controlled trials in infectious disease and
inflammatory bowel disease.
Vedanta Biosciences’ scientific co-founders have pioneered the
fields of innate immunity, Th17 and regulatory T cell biology, and
include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale),
Dr. Alexander Rudensky (tri-institutional Professor at the Memorial
Sloan-Kettering Institute, the Rockefeller University and Cornell
University), Dr. Dan Littman (Professor of Molecular Immunology at
NYU), Dr. Brett Finlay (Professor at the University of British
Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio
University).
Forward Looking StatementThis press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
regulatory filings for PureTech Health plc. These forward-looking
statements are based on assumptions regarding the present and
future business strategies of the company and the environment in
which it will operate in the future. Each forward-looking statement
speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company
nor any other party intends to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161018006822/en/
PureTechAllison Mead, +1-617-651-3156Director,
Communications and Investor Relationsamead@puretechhealth.com
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024